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Summary
Trk tyrosine kinases are receptors for members of the
neurotrophin family and are crucial for growth and
survival of specific populations of neurons. Yet, the
functions of neurotrophin-Trk signaling in postnatal
development as well as maintenance and plasticity of
the adult nervous system are less clear. We report
here the generation of mice harboring Trk knockin al-
leles that allow for pharmacological control of Trk ki-
nase activity. Nanomolar concentrations of either
1NMPP1 or 1NaPP1, derivatives of the general kinase
inhibitor PP1, inhibit NGF and BDNF signaling in
TrkAF592A and TrkBF616A neurons, respectively, while
no such Trk inhibition is observed in wild-type neu-
rons. Moreover, oral administration of 1NMPP1 leads
to specific inhibition of TrkAF592A, TrkBF616A, and
TrkCF167A signaling in vivo. Thus, Trk knockin mice
provide valuable tools for selective, rapid, and revers-
ible inhibition of neurotrophin signaling in vitro and
in vivo.
Introduction
The neurotrophins, nerve growth factor (NGF), brain-
derived neurotrophic factor (BDNF), neurotrophin-3
(NT-3), and neurotrophin-4/5 (NT-4/5) control many as-
pects of mammalian nervous system development.
Neurotrophin receptors are members of the Trk recep-
tor tyrosine kinase family; TrkA is a receptor for NGF,
TrkB for BDNF and NT-4/5, and TrkC for NT-3 (Huang
and Reichardt, 2003; Segal, 2003). NT-3 also signals
through TrkA and TrkB under certain circumstances
(Davies et al., 1995; Huang and Reichardt, 2003; Kuru-
villa et al., 2004). In addition, each of the neurotrophins
binds to the structurally unrelated neurotrophin recep-
tor p75. Many developmental roles of neurotrophins
and their receptors have been established. For exam-
ple, NGF-TrkA signaling is crucial for the survival and
growth of sympathetic neurons as well as small-diame-
ter nociceptive sensory neurons (Levi-Montalcini and
Booker, 1960; Smeyne et al., 1994). TrkB and TrkC are*Correspondence: dginty@jhmi.edualso critical for the development of specific populations
of peripheral nervous system (PNS) neurons (Klein et
al., 1994; Klein et al., 1993). Although less well charac-
terized, neurotrophins also appear to control many as-
pects of central nervous system (CNS) development
and modulate synaptic plasticity, metabolism, and neu-
rotransmission in the adult nervous system (for exam-
ples, see Guillin et al., 2001; McAllister et al., 1999; Xu
et al., 2003).
While standard gene inactivation approaches have
been useful for revealing the in vivo roles of neurotroph-
ins and their receptors in the mouse embryo, these
strategies are not well suited for the systematic analy-
sis of the functions of neurotrophins in the postnatal or
adult nervous system. Indeed, nearly all neurotrophin
and Trk null mice die perinatally. Conditional knockouts,
employing the Cre-LoxP strategy, have proven useful
for the analysis of at least some postnatal neurotrophin
functions, but limitations of this approach include the
dependence on a small number of available Cre recom-
binase strains, the low efficiency of Cre recombinase,
the lack of reversibility, and the poor temporal control
of target gene excision. Neutralizing antibodies have
also been widely used to study neurotrophin functions
(Goedert et al., 1978; Levi-Montalcini and Booker,
1960). However, this approach is greatly hampered by
issues of antibody specificity, complications associ-
ated with nonselective immune responses, the need for
repeated injections, and difficulties of antibody delivery
to the CNS. Furthermore, large quantities of specific
antibodies that selectively neutralize BDNF, NT-3, and
NT-4/5 are either limited or not available. Pharmacologi-
cal inhibitors of Trk kinase, notably the alkaloid K252a,
have also been widely used to study Trk function (Koi-
zumi et al., 1988; Ohmichi et al., 1992; Tapley et al.,
1992), but interpretations of experiments using inhibi-
tors such as K252a are difficult due to limited drug
specificity. Thus, there is a clear need for strategies al-
lowing potent, specific, rapidly acting, and reversible
inhibition of Trk signaling in order to study the roles of
neurotrophins during embryonic and postnatal devel-
opment and during the maintenance and plasticity of
the adult nervous system. An ideal approach would
combine the specificity of gene targeting and the tem-
poral control, reversibility, and rapid-acting properties
offered by a pharmacological approach.
Here we report mouse models that combine the ben-
efits of mouse genetics and pharmacology to probe the
functions of neurotrophins. We describe the generation
and characterization of mice harboring knockin muta-
tions in the murine Trk exons that encode regions of
the Trk kinase ATP binding pockets. A phenylalanine-
to-alanine substitution within kinase subdomain V of
each of the Trk receptors renders them sensitive to spe-
cific inhibition by membrane-permeable, small-mole-
cule PP1 derivatives, including 1NMPP1 (Bishop et al.,
2000). Such inhibition is specific, stable, and reversible
in vitro. Furthermore, in vivo administration of 1NMPP1
leads to elimination of specific populations of neurons
in Trk knockin mice but not in their wild-type litter-
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oGeneration of TrkAF592A, TrkBF616A,
band TrkCF617A Knockin Mice
cWe sought to develop a chemical-genetic strategy that
kenables specific, rapid, and reversible inhibition of en-
bdogenous Trk kinases. Mutations within the ATP bind-
fing pocket of the non-receptor tyrosine kinase v-Src
(I338) renders it susceptible to inhibition by small-mole-
tcule derivatives of the general kinase inhibitor PP1
1(Bishop et al., 2000). At the location corresponding to
kv-Src I338, TrkA592, TrkB616, and TrkC617, all Trk pro-
hteins have a phenylalanine (F) (Figure 1A). Preliminary
tfindings showed that substitution of TrkA F592 with
geither a glycine (G) or an alanine (A) does not affect
sNGF-dependent TrkA signaling in PC12 cells, but does
orender the mutant TrkA receptor susceptible to inhibi-
otion by 1NMPP1 and 1NaPP1, derivatives of PP1 (data
nnot shown). Importantly, neither 1NMPP1 nor 1NaPP1
saffects the activity of wild-type TrkA. The success of
wthese PC12 cell experiments prompted us to employ a
dgene-targeting approach to generate knockin mice in
fwhich the activities of the endogenous Trk proteins
Care susceptible to specific inhibition by PP1 deriva-
Ttives. The gene-targeting strategies used to generate
TrkAF592A, TrkBF616A, and TrkCF617A knockin mice are lFigure 1. Generation of TrkAF592A, TrkBF616A, and TrkCF617A Knockin Mice
(A) Sequence alignment of mouse TrkA F592, TrkB F616, and TrkC F617 and the corresponding amino acid residues surrounding Src I338
within the ATP binding pocket of protein kinase subdomain V.
(B–D) Targeting strategies for TrkAF592A, TrkBF616A, and TrkCF617A knockin mice. In the targeting vectors, the exons carrying the F-A mutations
and FRT-Neo-FRT cassettes are flanked by two LoxP sites. Crosses between the chimeric animals carrying the targeted allele with a mouse
line expressing FlpE recombinase in the germline leads to excision of the FRT-Neo-FRT cassette. The final TrkAF592A, TrkBF616A, and TrkCF617A
targeted alleles contain the targeted exon harboring the F-A mutation, an intron with one FRT site, and flanking introns with LoxP sites.utlined in Figures 1B–1D. Chimeric mice were ob-
ained following blastocyst injection of targeted ES
ells, and the neomycin resistant cassettes used for ES
ell selection were excised upon crossing the chimeric
rk mice with mice expressing FlpE recombinase in
erm cells. As a result, the TrkAF592A, TrkBF616A, and
rkCF617A knockin mice each harbor a single point mu-
ation, changing F to A within the ATP binding pocket
f kinase subdomain V, and contain approximately 100
ase pairs of FRT and LoxP sequences located in adja-
ent introns. Heterozygous mice harboring the Trk F-A
nockin mutations were backcrossed to a C57BL/6
ackground, and homozygous mice were obtained
rom heterozygous intercrosses.
Unlike each of the Trk null mice, which dies perina-
ally (Klein et al., 1994; Klein et al., 1993; Smeyne et al.,
994), homozygous TrkAF592A, TrkBF616A, and TrkCF617A
nockin mice are viable and fertile, with no obvious be-
avioral abnormality. These findings support the notion
hat the Trk F-A knockin mutations do not abolish Trk
ene function. To further address this issue, BDNF-TrkB
ignaling was assessed using cultured cortical neurons
btained from postnatal day 0.5 (P0.5) TrkBF616A pups
r wild-type littermates. The BDNF dose-responsive-
ess for activation of TrkB phosphorylation and down-
tream effectors, Akt and MAPK, is comparable for
ild-type and TrkBF616A neurons (Figure 2A). A detailed
escription of the TrkBF616A kinase kinetics in trans-
ected cells is described elsewhere (N.D. Okerlund,
. Zhang, K.M. Shokat, and P.M. England, submitted).
hese findings indicate that the F616A mutation has
ittle or no effect on BDNF-mediated TrkB signaling.
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15Figure 2. Pharmacological Inhibition of BDNF-TrkBF616A Signaling in Cortical Neurons
(A) Comparable BDNF dose responsiveness for activation of TrkB phosphorylation and its downstream effectors in wild-type and TrkBF616A
neurons. Cultured cortical neurons obtained from P0.5 TrkBF616A homozygous mutant mice or their wild-type littermates were grown in vitro
for 5 days, treated with various concentrations of BDNF for 20 min, and P-Trk, P-Akt, and P-Erk signaling was assessed by immunoblot.
Differences in basal levels of P-Akt in TrkBF616A and wild-type cultures were not observed in other experiments.
(B) Molecular structures of PP1 and its derivatives.
(C and D) Cultured cortical neurons from TrkBF616A homozygous mutant mice or their wild-type littermates were treated with BDNF (50 ng/ml)
for 20 min in the presence of (C) different PP1 derivatives or K252a or (D) various concentrations of K252a prior to BDNF exposure. Protein
extracts were subjected to immunoblot analysis using antibodies against P-Trk(Y490), P-Akt, P-Erks1/2, and α-tubulin.Trk F-A Activity Is Specifically and Potently Inhibited
by 1NMPP1 and 1NaPP1 In Vitro
To ask if one or more of the PP1 derivatives inhibits the
mutant Trk F-A kinases, we tested several PP1 deriva-
tives (100 nM; Figure 2B) for their ability to block BDNF
signaling in cortical neurons cultured from TrkBF616A
mice. Both 1NaPP1 and 1NMPP1 achieved complete
inhibition of TrkBF616A autophosphorylation and signal-
ing, whereas the same concentration of 2NMPP1 led
to partial inhibition, and CPPU had no inhibitory effect
(Figure 2C). Interestingly, K252a (100 nM), the com-
monly used inhibitor of Trk kinases, did not inhibit
TrkBF616A signaling, although it did block the activity
of wild-type TrkB (Figure 2D). This result indicates that
K252a and PP1 derivatives may interact with common
residues within the TrkB ATP binding pocket and that
the F616A mutation may diminish K252a binding to
TrkB.
Side-by-side drug efficacy comparisons were thus
carried out with the most potent PP1 derivatives,
1NMPP1 and 1NaPP1. Both drugs were found to po-
tently and specifically inhibit TrkBF616A kinase activity
in cortical neurons cultured from either wild-type or
TrkBF616A mutant embryos (Figure 3A; data not shown).
The IC50 values for 1NaPP1 and 1NMPP1 inhibition of
TrkBF616A were both estimated to be approximately 3
nM. In marked contrast, no inhibition of TrkB activity
was observed in wild-type cortical neurons treated with
either 1NaPP1 or 1NMPP1, even at concentrations as
high as 10 M (Figure 3A; data not shown).
Similar findings were made in experiments designedto test the efficacy and specificity of 1NMPP1 inhibition
of TrkAF592A signaling. Since NGF and TrkA are required
for survival of sympathetic neurons (Klein et al., 1994;
Levi-Montalcini and Booker, 1960), we cultured superior
cervical ganglion (SCG) neurons from P0.5 TrkAF592A
mice and their wild-type littermates and assessed their
survival after treatment with 1NMPP1. NGF-TrkAF592A
signaling was effectively blocked by 100 nM 1NMPP1,
as shown by complete inhibition of NGF-dependent sur-
vival of sympathetic neurons obtained from TrkAF592A
mice (Figures 3B and 3C). No inhibitory effect was ob-
served for wild-type sympathetic neurons. These find-
ings indicate that 1NMPP1 selectively and potently in-
hibits the activities of TrkAF592A and TrkBF616A, whereas
a high concentration of this compound does not affect
wild-type Trk receptor signaling.
1NMPP1 Inhibition Is Stable and Reversible In Vitro
One of the appealing advantages of using competitive
inhibitors to study enzyme function is the reversible na-
ture of their action, which in the case of 1NMPP1 may
allow precise temporal control over Trk F-A signaling.
To assess the extent of reversibility of 1NMPP1-medi-
ated inhibition of TrkBF616A signaling in cortical neu-
rons, we first exposed TrkBF616A neurons for 2 hr to
either 1NMPP1 (100 nM) or DMSO vehicle control,
washed away the drug or vehicle, and then reexposed
neurons to either DMSO or 1NMPP1. BDNF-TrkBF616A
signaling was completely inhibited in 1NMPP1-treated
cortical neurons, but is then reestablished after
1NMPP1 washout, indicating that 1NMPP1 inhibition of
Neuron
16Figure 3. 1NMPP1 Is a Potent and Specific Inhibitor of TrkBF616A and TrkAF592A Signaling
(A) 1NMPP1 specifically inhibits BDNF signaling in TrkBF616A cortical neurons but not wild-type neurons. Cultured cortical neurons from P0.5
TrkBF616A homozygous mutant mice or their wild-type littermates were treated with the indicated concentrations of 1NMPP1 (2 hr) prior to
BDNF exposure (50 ng/ml; 20 min).
(B and C) 1NMPP1 specifically inhibits TrkAF592A but not wild-type TrkA signaling. (B) Phase-contrast images of wild-type (left) and TrkAF592A
(right) neurons treated with NGF (50 ng/mL) + vehicle (DMSO) or NGF (50 ng/mL) + 1NMPP1 (100 nM and 1000 nM concentrations for TrkAF592A
and wild-type neurons, respectively). Arrows indicate degenerating neurites in TrkAF592A neuronal cultures treated with 1NMPP1. (C) Cultures
of sympathetic neurons established from wild-type and TrkAF592A mice were grown in media containing 50 ng/mL NGF for 3–5 days in vitro
and then treated with anti-NGF, NGF (50 ng/mL) alone, or various concentrations of 1NMPP1 for 24 hr. After treatment, cells were fixed and
stained with Hoechst 33258. Apoptotic cells were scored based on nuclear morphology. The amount of neuronal cell death is presented as
mean ± SEM from three independent experiments. *p < 0.05, significantly different as ascertained by one-way ANOVA followed by a Tukey’s
Multiple Comparision test. Scale bar, 100 M.TrkBF616A is reversible (Figure 4A). Additionally, in con- i
ctrast to the commonly used nonselective Trk inhibitor











Figure 4. 1NMPP1 Is a Stable and Reversible Inhibitor of TrkBF616A t
Signaling In Vitro
t
Cultured cortical neurons from TrkBF616A homozygous mutant mice s
were treated with 100 nM 1NMPP1 for 2 hr and then with either
oDMSO or 100 nM 1NMPP1 for 2 hr (A) or the indicated times (B)
gand then BDNF (50 ng/ml) for 20 min. Note that removal of 1NMPP1
for 2 hr restores BDNF activation of TrkBF616A. mn vitro stability experiments indicate that a single appli-
ation of 1NMPP1 (100 nM) to cultured neurons led to
ustained inhibition of TrkBF616A signaling for at least 3
ays, the duration of the experiment (Figure 4B). These
esults, taken together, indicate that 1NMPP1 is a po-
ent, specific, stable, and reversible inhibitor of
rkAF592A and TrkBF616A signaling in neurons.
NMPP1 Inhibits Neurotrophin Signaling
n Trk F-A Mice In Vivo
e next sought to determine the efficacy and specific-
ty of 1NMPP1 inhibition of Trk F-A signaling in vivo.
e reasoned that 1NMPP1 application to TrkAF592A,
rkBF616A, and TrkCF617A embryos, but not to their wild-
ype littermates, should result in phenotypes similar to
hose observed in Trk null mice. The dependence of
ympathetic neurons on TrkA, nodose ganglion neurons
n TrkB, and parvalbumin (PV)-positive dorsal root gan-
lion (DRG) neurons on TrkC is evident from the dra-
atic cell loss in mice harboring null mutations in the
Chemical-Genetics and Neurotrophin Signaling
17respective Trk and neurotrophin genes (Klein et al.,
1994; Klein et al., 1993; Smeyne et al.,1994). We there-
fore assessed the integrity of SCG, nodose ganglia, and
PV-positive DRG neurons in the Trk F-A knockin mice.
Cell counts revealed no significant differences in SCG,
nodose ganglion, and PV-positive DRG neuron num-
bers between Trk F-A knockin pups and their wild-type
littermates at P0.5 (Figures 5–7). Therefore, consistent
with the aforementioned results of in vitro experiments,
the F-A knockin mutations do not adversely affect neu-
rotrophin signaling in vivo. To assess the extent of
1NMPP1 inhibition of NGF-TrkAF592A signaling in vivo,
we administered 1NMPP1 in drinking water (25 M) to
TrkAF592A heterozygous mice throughout their pregnan-
cies after they were mated to mice of the same geno-
type. In parallel experiments, 1NMPP1 was admin-
istered in the drinking water together with two
intraperitoneal boosting injections (16.6 ng/g body
weight) at E15 and E17. In both sets of experiments,
neuronal counts of SCG and nodose ganglion were
done in the P0.5 progeny of 1NMPP1 or vehicle-treated
TrkAF592A mice. SCG counts revealed approximately
50% neuronal loss in TrkAF592A homozygous offspring
whose mothers received 1NMPP1, whereas no effect
was observed in wild-type littermates (Figure 5). This
degree of cell loss is comparable to that observed in
P0 TrkA null mice (Fagan et al., 1996). As expected,
nodose ganglion neurons, which depend on TrkB sig-
naling for survival, were not affected in these experi-
ments, indicating that TrkB signaling is not affected by
1NMPP1 treatment of TrkAF592A mice (data not shown).
Comparable experiments were carried out to assess
the efficacy and specificity of 1NMPP1 inhibition of
TrkBF616A and TrkCF617A signaling in vivo. Nodose gan-
glion neuron counts revealed 60% neuronal loss in
TrkBF616A homozygous offspring whose mothers were
treated with 1NMPP1, while no cell loss was observed
in wild-type littermates. Drinking water administrationFigure 5. 1NMPP1 Specifically Inhibits TrkAF592A Signaling In Vivo
(A) Nissl staining of superior cervical ganglia.
(B) Cell counts of superior cervical ganglia at P0.5. Heterozygous females that were mated with heterozygous males received either vehicle
DMSO or 25 M 1NMPP1 in drinking water beginning 1 day PC and continued for the duration of the pregnancy. Some animals also received
two boosting i.p. injections (16.6 ng/g body weight) at E15 and E17. Results are presented as mean ± SEM from four independent experiments.
*p < 0.05; one-way ANOVA followed by a Bonferroni post hoc test. Scale bar, 100 m.of 1NMPP1 was sufficient to block TrkBF616A signaling
in nodose ganglion neurons; a comparable amount of
nodose ganglion cell loss was observed in experiments
with and without the boosting injections (Figure 6). As
expected, SCG neuron viability was not affected in
either group (data not shown). Moreover, we observed
a dramatic decrease of PV-positive fibers in the lumbar
spinal cord and PV-positive DRG neurons in 1NMPP1-
treated TrkCF617A mice, but not in their wild-type litter-
mates (Figure 7). This degree of proprioceptive neuron
loss is comparable to that observed in Nt3 null mice
(Ernfors et al., 1994). Taken together, these results indi-
cate that 1NMPP1, administered orally, effectively and
specifically inhibits TrkAF592A, TrkBF616A, and TrkCF617A
signaling in vivo.
Discussion
Here we describe mouse models that allow for potent,
specific, and reversible inhibition of Trk kinase activity
in vitro and in vivo. Our chemical-genetic approach for
studying neurotrophin-Trk receptor signaling combines
the specificity of gene targeting and the convenience,
rapid temporal control, and reversibility of competitive
pharmacology. A similar strategy should prove useful
for studying the neural functions of other growth factor
receptors, including c-Ret, FGF receptors, EGF recep-
tors, and Eph receptors.
Major advantages of the chemical-genetic approach
to studying neurotrophin signaling include the specific-
ity of inhibition and the availability of a compelling con-
trol, the wild-type littermate. These benefits circumvent
the concerns of typical pharmacological experiments.
There are more than 500 kinases in the protein kinase
superfamily, and they exhibit a remarkable degree of
conservation within their ATP binding domains. The
most commonly used protein kinase inhibitors compete
with ATP binding, but the interpretations of such experi-
Neuron
18Figure 6. 1NMPP1 Specifically Inhibits TrkBF616A Signaling In Vivo
(A) Nissl staining of nodose ganglia.
(B) Cell counts of nodose ganglia at P0.5. Heterozygous females that were mated with heterozygous males received either vehicle DMSO or
25 M 1NMPP1 in drinking water beginning 1 day PC and continued for the duration of the pregnancy. Some animals also received two
boosting i.p. injections (16.6 ng/g body weight) at E15 and E17. Results are presented as mean ± SEM from four independent experiments.
*p < 0.05; one-way ANOVA followed by a Bonferroni post hoc test. Scale bar, 100 m.control experiments that provide a measure of specific- TrkB is observed with drug concentrations as high as
Figure 7. 1NMPP1 Specifically Inhibits TrkCF617A Signaling In Vivo
(A) Parvalbumin staining of lumber spinal cord and dorsal root ganglia.
(B) Cell counts of parvalbumin-positive neurons in L5 dorsal root ganglia at P0.5. Heterozygous females that were mated with heterozygous
males received either vehicle DMSO or 25M 1NMPP1 in drinking water beginning 1 day PC and continued for the duration of the pregnancy.
These animals also received two boosting i.p. injections (16.6 ng/g body weight) at E13 and E15. Results are presented as mean ± SEM from
four independent experiments. *p < 0.05; one-way ANOVA followed by a Bonferroni post hoc test. Scale bar, 100 m.ments are hampered by the uncertainty of inhibitor i
especificity. Indeed, the most commonly used Trk inhibi-
tor, K252a, also blocks the activities of other tyrosine h
vkinases as well as a number of serine/threonine ki-
nases, including MLCK and PKC (Kase et al., 1987; Na- t
skanishi et al., 1988). Paradoxically, high concentrations
of K252a can actually support survival of neurotrophin- F
idependent neurons, consistent with the existence of
multiple unidentified targets of this drug (Borasio, 1990; 1
wRoux et al., 2002). Furthermore, it is difficult to designty of K252a or the other ATP competitive inhibitors. For
xperiments employing the Trk F-A mice described
ere, an excellent control of 1NMPP1 specificity is pro-
ided by wild-type littermates. The sole difference be-
ween experimental and control neurons is the F-A sub-
titution, which is by itself functionally silent. The Trk
-A mutants reported here are potently and specifically
nhibited by the PP1 derivatives. Indeed, the IC50 of
NMPP1 and 1NaPP1 inhibition of Trk F-A neurons is
3 nM, whereas no inhibition of wild-type TrkA and
Chemical-Genetics and Neurotrophin Signaling
1910 M. This high degree of inhibitor potency compares
quite favorably to the most potent kinase inhibitors, in-
cluding the heat-stable inhibitor of PKA, PKI (Mitchell
et al., 1995). Furthermore, the PP1 derivatives are ex-
tremely stable in vitro, as compared to other inhibitors.
While K252a experiments require drug replenishment
every 12 to 24 hr, a single dose of 1NMPP1 leads to
potent inhibition of Trk F-A signaling for at least 3 days.
Finally, 1NMPP1 inhibition of Trk F-A mutants is both
fast acting and reversible. Along with inhibitor specific-
ity, these convenient features of 1NMPP1 pharmacol-
ogy should enable a wide range of future experiments
addressing Trk receptor function.
Another advantage of the Trk F-A knockin mice is the
convenient mode of drug administration. PP1 inhibitors
have proven effective when administered through IP in-
jection or drinking water. Drinking water administration
of 1NMPP1 effectively blocks Trk F-A signaling in vivo,
as shown by our findings that oral administration
of 1NMPP1 to pregnant TrkAF592A, TrkBF616A, and
TrkCF617A heterozygous mice leads to loss of selective
populations of neurons in homozygous Trk F-A em-
bryos. 1NMPP1 inhibition of Trk F-A signaling in vivo
is robust. The SCG of 1NMPP1-treated TrkAF592A mice
exhibit w50% of the normal complement of sympa-
thetic neurons. This result compares favorably to the
extent of cell loss observed in TrkA null mice at P0.5
(Fagan et al., 1996). Similarly, comparable to that ob-
served in Nt3 null mice (Ernfors et al., 1994), PV-positive
DRG neurons are almost completely lost in 1NMPP1-
treated TrkCF617A mice. The destruction of specific pop-
ulations of neurons in Trk F-A mice but not control
littermates whose mothers were treated with 1NMPP1
indicates that this inhibitor can pass the placental bar-
rier to selectively inhibit Trk F-A signaling in embryos in
utero. Thus, the oral route of 1NMPP1 delivery will likely
prove useful for experiments designed to establish the
precise developmental times at which Trk signaling
events are required for aspects of neuronal develop-
ment. Importantly, 1NMPP1 can also pass the blood-
brain barrier. Indeed, Wang et al. showed that 1NMPP1
effectively inhibits the activity of a mutant CaMKII pro-
duced by transgenic overexpression in the adult brain
(Wang et al., 2003). Thus, low molecular weight, mem-
brane-permeable PP1 derivatives are well suited for in
vivo functional experiments requiring precise temporal
control over Trk F-A receptor activity.
Much remains to be learned about the postnatal
functions of neurotrophin signaling, since the lethality
of neurotrophin and Trk null mice has severely limited
their usefulness in addressing neurotrophin function
during much of CNS development. The Trk F-A knockin
mice, unlike Trk null mice, are healthy and have no ob-
servable behavioral or physiological phenotype. We
therefore anticipate that the Trk F-A mice will be valu-
able for assessing the requirement of Trks in the post-
natal development of the nervous system. Pharmaco-
logical inhibition of TrkAF592A in postnatal mice should
allow for a determination of the role of NGF-TrkA signal-
ing during development of basal forebrain cholinergic
neurons, which express high levels of TrkA. Similarly,
inhibition of TrkBF616A and TrkCF617A in double knockin
mice should provide insights into the potentially redun-
dant developmental roles of TrkB and TrkC, which arecoexpressed in many populations of postnatal CNS
neurons. The Trk F-A mice should also prove useful for
addressing adult functions of neurotrophins, including
their potential roles in neuronal survival, axon and den-
drite maintenance, neural regeneration, adult stem cell
differentiation and growth, neurotransmission, neural
plasticity, and behavior. Finally, the rapid and reversible
nature of 1NMPP1 inhibition of Trk F-A signaling should
enable studies that define the precise temporal contri-
butions of neurotrophin-Trk signaling events during de-
velopment, plasticity, and behavior.
In summary, we have developed mouse models that
allow for specific, temporal, and reversible inhibition
of neurotrophin-Trk signaling in vitro and in vivo. The
TrkAF592A, TrkBF616A, and TrkCF617A knockin mice
should prove useful for elucidation of the functions of
neurotrophins during embryonic and postnatal devel-
opment as well as during maintenance and plasticity of
the adult nervous system.
Experimental Procedures
Generation of TrkAF592A, TrkBF616A, and TrkCF617A Mutant Mice
Murine TrkA F592, TrkB F616, and TrkC F617 are the residues corre-
sponding to Src I338 used previously to establish specific chemical
inhibition of Src kinase activity (Bishop et al., 2000). The trk exons
encoding these amino acids were altered by homologous recombi-
nation. To construct the targeting vector for TrkAF592A, a 12.3 kb
Aat II-Spe I fragment containing exon 12 of TrkA was isolated from
a 129J mouse genomic BAC library (RPCI-22). The targeting vector
was comprised of a 1.0 kb short arm, a 7.6 kb long arm, a 3.7 kb
targeted sequence carrying the F592A mutation, and the FRT-Neo-
FRT cassette flanked by two loxP sites. To construct the targeting
vector for TrkBF616A, a 11.2 kb Bsr BI fragment containing exon 14
of TrkB was isolated from a 129J mouse genomic BAC library
(RPCI-22). The targeting vector was comprised of a 0.7 kb short
arm, a 7.3 kb long arm, 3.2 kb targeted sequence carrying the
F616A mutation, and the FRT-Neo-FRT cassette flanked by two
loxP sites. To construct the targeting vector for TrkCF617A, a 11.7
kb Hind III fragment containing the target exon of TrkC was isolated
from a 129J mouse genomic BAC library (RPCI-22). The targeting
vector was comprised of a 3.8 kb short arm, a 7.0 kb long arm, a
0.9 kb targeted sequence carrying the F617A mutation, and the
FRT-Neo-FRT cassette flanked by two loxP sites. Mutagenesis was
done using a site-directed PCR mutagenesis strategy (Stratagene).
Linearized targeting vectors were electroporated into 129.1 mouse
strain embryonic stem (ES) cells, and ES cell clones were selected
with G418 (300 g/ml). ES cell clones were screened by PCR, and
results were confirmed by Southern blotting. Four positive ES
clones for each construct were injected into C57BL/6 blastocysts,
which were then introduced into pseudopregnant females. Chi-
meric animals were mated with C57BL/6 to produce heterozygous
animals, and these mice were subsequently crossed with mice ex-
pressing FlpE recombinase (Rodriguez et al., 2000) in germ cells
(kindly provided by Susan Dymecki, Harvard University) to excise
the neo cassettes. All analyses were performed on mice with a
129J and C57BL/6 hybrid genetic background. All procedures relat-
ing to animal care and treatment conformed to institutional and
NIH guidelines.
Chemical Synthesis of 1NMPP1 and 1NaPP1
1NMPP1 and 1NaPP1 were synthesized as described previously
(Benjamin et al., 2003; Wang et al., 2003).
Sympathetic Neuron Survival Assays
Sympathetic neurons were prepared from superior cervival ganglia
from postnatal day 0.5 (P0.5) mice as previously described (Kuru-
villa et al., 2000). Cells were washed three times with Dulbecco’s
Modified Eagle Medium (DMEM; Invitrogen) and then subjected to
the various treatments as indicated in the figure legends. Cell sur-
Neuron
20vival assays were performed as previously described (Kuruvilla et B
aal., 2000).
p
Cortical Neuron Culture B
High-density cortical neuron cultures were prepared as previously t
described (Rosen et al., 1994), except that the cells were main- r
tained in Neurobasal-SFM medium supplemented with B-27 and D
0.5 mM Glutamine (Invitrogen). Cortical neurons were used 5 days c
after plating for treatments and immunoblot experiments as indi- E
cated in the figure legends. Cells were lysed with boiling Laemmli




ICell lysates were resolved by SDS-PAGE and immunoblotted with
tantibodies against P-TrkA(Y490), P-Akt (Ser473), or P-Erk1/2 (Cell
6Signaling). Normalization for protein amounts was done by re-
probing the immunoblots with an antibody against α-tubulin (Santa G
Cruz Biotechnology). All blocking and washing solutions for immu- o
noblotting were using TBS (50 mM Tris-HCl [pH 7.5] and 150 mM f
NaCl) containing 5% milk and 0.1% Tween-20. G
l
Immunostaining Procedures t
Embryonic tissues were fixed in PBS containing paraformaldehyde
H(PFA, 4%), cryoprotected overnight in PBS containing 30%
rsucrose, and 10 m sections were prepared using a cryostat. For
Kparvalbumin immunostaining, sections were blocked in PBS con-
ktaining BSA (1%) and Triton X-100 (0.1%) for 1.5 hr. Primary anti-
cbody (PV28, SWANT) was diluted 1:1500 in blocking solution and
cincubated overnight at 4°C. Fluorescent secondary antibody (Mo-
Rlecular Probes) was diluted 1:750 in blocking solution.
K
Neuronal Counts J
Tissues were fixed in PBS containing 4% paraformaldehyde (PFA), t
cryoprotected overnight in PBS containing 30% sucrose, and fro- a
zen. Cyrostat sections (10 m) of superior cervical ganglion (SCG) K
and nodose ganglion were prepared and stained with a solution B
containing 0.5% cresyl violet, and cells with visible nucleoli were t
counted as neurons (Lonze et al., 2002). For SCG cell count, every a
fifth section was collected, and nissl staining was performed. Area
K
was measured on all sections, and three representative sections
a
were counted for SCG. For nodose ganglion cell counts, every fifth
n
section was collected, nissl staining was performed, and every sec-
Ktion was counted. For dorsal root ganglion (DRG) cell counts, every
afourth cryostat section (10 m) was collected. Parvalbumin
iimmunostaining was performed on all sections, and every section
Kwas counted. Statistical analysis was performed using one-way
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